Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it will present at the Rodman & Renshaw 13
Annual Healthcare Conference on September 12, 2011, at 3:15 p.m. Eastern Time at the Waldorf Astoria Hotel in New York, NY.
Rexahn’s President and Chief Operating Officer, Rick Soni, and Chief Financial Officer, Ted Jeong, will provide a strategic business overview of the Company, including a discussion of its R&D pipeline.
For more information about the Rodman & Renshaw 13
Annual Global Healthcare Conference, go to:
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin
, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit